Commission authorises medicine to treat early stages of Alzheimer’s disease
The European Commission has granted EU marketing authorisation for Kisunla, a medicine to treat mild cognitive impairment, including mild dementia in the early stages of Alzheimer’s disease. Kisunla can help to slow down the progression of cognitive and functional issues associated with Alzheimer’s disease in certain patients. The authorisation is based on the positive scientific assessment …